コンポーネント：
治療オプション：
Oliinyk Elizabeth Ivanovna 、薬局による医学的評価、 最終更新日：26.06.2023
アテンション！ そのこのページの情報は医療専門家のみを対象としています！ その情報が収集したオープン源を含めることが可能である重大な誤差! 注意して、このページ上のすべての情報を再確認してください！
GSL
For the relief of mild to moderate pain including rheumatic and muscular pain, backache, neuralgia, migraine, headache, dental pain, dysmenorrhoea, feverishness and for the relief of the symptoms of cold and influenza.
For the relief of migraine-headaches, backache, dental pain, neuralgia and period pains as well as rheumatic and muscular pains.
Ibulam relieves pain and reduces inflammation and temperature as well as relieving headaches and other types of pain. It also relieves cold and flu symptoms.
Purpose
Pain reliever/fever reducer
Uses
- temporarily relieves minor aches and pains due to:
- headache
- the common cold
- toothache
- muscular aches
- backache
- menstrual cramps
- minor pain of arthritis
- temporarily reduces fever
Ibulam is indicated for its analgesic and anti-inflammatory effects in the treatment of rheumatoid arthritis (including juvenile rheumatoid arthritis or Still's disease), ankylosing spondylitis, osteoarthritis and other non-rheumatoid (seronegative) arthropathies.
In the treatment of non-articular rheumatic conditions, Ibulam is indicated in periarticular conditions such as frozen shoulder (capsulitis), bursitis, tendinitis, tenosynovitis and low back pain; Ibulam can also be used in soft-tissue injuries such as sprains and strains.
Ibulam is also indicated for its analgesic effect in the relief of mild to moderate pain such as dysmenorrhoea, dental and post-operative pain and for symptomatic relief of headache including migraine headache.
Ibulam is indicated in adults and pediatric patients six months and older for the:
- management of mild to moderate pain and the management of moderate to severe pain as an adjunct to opioid analgesics
- reduction of fever
Treatment of a haemodynamically significant patent ductus arteriosus in preterm newborn infants less than 34 weeks of gestational age.
Ibulam is indicated to close a clinically significant patent ductus arteriosus (PDA) in premature infants weighing between 500 and 1500 g, who are no more than 32 weeks gestational age when usual medical management (e.g., fluid restriction, diuretics, respiratory support, etc.) is ineffective. The clinical trial was conducted among infants with an asymptomatic PDA. However, the consequences beyond 8 weeks after treatment have not been evaluated; therefore, treatment should be reserved for infants with clear evidence of a clinically significant PDA.
